Disruption of 3CLpro protease self-association by short peptides as a potential route to broad spectrum coronavirus inhibitors

被引:2
|
作者
ElSawy, Karim M. [1 ,2 ]
Alminderej, Fahad M. [1 ]
Caves, Leo S. D. [2 ]
机构
[1] Qassim Univ, Coll Sci, Dept Chem, Buraydah, Saudi Arabia
[2] Univ York, York Cross Disciplinary Ctr Syst Anal YCCSA, York, N Yorkshire, England
来源
关键词
COVID-19; inhibitors; blind drug docking; 3CLpro dimerization; coronavirus inhibitors; RESPIRATORY SYNDROME CORONAVIRUS; MOLECULAR-DYNAMICS SIMULATION; FDA-APPROVED INHIBITORS; SARS-CORONAVIRUS; HOT-SPOTS; 3C-LIKE PROTEASE; MAIN PROTEASE; DOCKING; SARS-COV-2; RIBAVIRIN;
D O I
10.1080/07391102.2021.1996462
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Coronaviruses have posed a persistent threat to human health over the last two decades. Despite the accumulated knowledge about coronavirus-related pathogens, development of an effective treatment for its new variant COVID-19 is highly challenging. For the highly-conserved and main coronavirus protease 3CLpro, dimerization is known to be essential for its catalytic activity and thereby for virus proliferation. Here, we assess the potential of short peptide segments to disrupt dimerization of the 3CLpro protease as a route to block COVID-19 proliferation. Based on the X-ray structure of the 3CLpro dimer, we identified the SPSGVY126QCAMRP dodecapeptide segment as overlapping the hotspot regions on the 3CLpro dimer interface. Using computational blind docking of the peptide to the 3CLpro monomer, we found that the SPSGVY126QCAMRP peptide has favourable thermodynamic binding (DG 1/4 -5.93 kcal/mol) to the hotspot regions at the 3CLpro dimer interface. Importantly, the peptide was also found to preferentially bind to the hotspot regions compared to other potential binding sites lying away from the dimer interface (DDG=-1.31 kcal/mol). Docking of peptides corresponding to systematic mutation of the V125 and Y126 residues led to the identification of seven peptides, SPSGHAQCAMRP, SPSGVTQCAMRP, SPSGKPQCAMRP, SPSGATQCAMRP, SPSGWLQCAMRP, SPSGAPQCAMRP and SPSGHPQCAMRP, that outperform the wild-type SPSGVY126QCAMRP peptide in terms of preferential binding to the 3CLpro dimer interface. These peptides have the potential to disrupt 3CLpro dimerization and therefore could provide lead structures for the development of broad spectrum COVID19 inhibitors.
引用
收藏
页码:13901 / 13911
页数:11
相关论文
共 29 条
  • [1] Design of peptide-based coronavirus inhibitors that target disruption of 3CLpro protease self-association
    ElSawy, Karim M.
    Alminderej, Fahad M.
    Caves, Leo S. D.
    MOLECULAR SYSTEMS DESIGN & ENGINEERING, 2022, 7 (09) : 1138 - 1153
  • [2] Development of broad-spectrum halomethyl ketone inhibitors against coronavirus main protease 3CLpro
    Bacha, Usman
    Barrila, Jennifer
    Gabelli, Sandra B.
    Kiso, Yoshiaki
    Amzel, L. Mario
    Freire, Ernesto
    CHEMICAL BIOLOGY & DRUG DESIGN, 2008, 72 (01) : 34 - 49
  • [3] Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro
    Bacha, U
    Barrila, J
    Velazquez-Campoy, A
    Leavitt, SA
    Freire, E
    BIOCHEMISTRY, 2004, 43 (17) : 4906 - 4912
  • [4] Identification of novel inhibitors of the SARS coronavirus main protease 3CLpro
    Bacha, UM
    Barrila, JA
    Freire, EI
    PROTEIN SCIENCE, 2004, 13 : 79 - 79
  • [5] A Patent Review on SARS Coronavirus Main Protease (3CLpro) Inhibitors
    Chia, C. S. Brian
    Xu, Weijun
    Shuyi Ng, Pearly
    CHEMMEDCHEM, 2022, 17 (01)
  • [6] Development of potent inhibitors of the SARS associated coronavirus protease 3CLpro
    Bacha, UM
    Barrila, JA
    Velazquez-Campoy, A
    Leavitt, S
    Freire, E
    BIOPHYSICAL JOURNAL, 2004, 86 (01) : 97A - 97A
  • [7] Potential Broad Spectrum Inhibitors of the Coronavirus 3CLpro: A Virtual Screening and Structure-Based Drug Design Study
    Berry, Michael
    Fielding, Burtram C.
    Gamieldien, Junaid
    VIRUSES-BASEL, 2015, 7 (12): : 6642 - 6660
  • [8] The development of Coronavirus 3C-Like protease (3CLpro) inhibitors from 2010 to 2020
    Liu, Yuzhi
    Liang, Chengyuan
    Xin, Liang
    Ren, Xiaodong
    Tian, Lei
    Ju, Xingke
    Li, Han
    Wang, Yongbo
    Zhao, Qianqian
    Liu, Hong
    Cao, Wenqiang
    Xie, Xiaolin
    Zhang, Dezhu
    Wang, Yu
    Jian, Yanlin
    EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2020, 206
  • [9] Biflavonoid as potential 3-chymotrypsin-like protease (3CLpro) inhibitor of SARS-Coronavirus
    Hartini, Yustina
    Saputra, Bakti
    Wahono, Bryan
    Auw, Zerlinda
    Indayani, Friska
    Adelya, Lintang
    Namba, Gabriel
    Hariono, Maywan
    RESULTS IN CHEMISTRY, 2021, 3
  • [10] Potential inhibitors of coronavirus 3-chymotrypsin-like protease (3CLpro): an in silico screening of alkaloids and terpenoids from African medicinal plants
    Gyebi, Gideon A.
    Ogunro, Olalekan B.
    Adegunloye, Adegbenro P.
    Ogunyemi, Oludare M.
    Afolabi, Saheed O.
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2021, 39 (09): : 3396 - 3408